Interestingly, the knock-down of NLRP3 or its inhibition was shown to diminish microglial activation as well as α-synuclein pathology and DA degeneration, indicating that anti-inflammatory treatment strategies can be a therapeutic option for PD [167,168]. Here, SNCA is linked to Parkinson disease.